Cassava Sciences INC (FLNA) — SEC Filings

Overview

Cassava Sciences INC (FLNA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Dec 22, 2025: Cassava Sciences, Inc. filed an 8-K/A on December 22, 2025, to amend a previous filing regarding events that occurred on October 21, 2025. The amendment pertains to the departure of a director, election of a new director, and compensatory arrangements for certain officers. The company is incorporate

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Cassava Sciences INC is neutral.

Filing Type Overview

Cassava Sciences INC (FLNA) has filed 37 8-K, 3 8-K/A, 6 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Dec 23, 2025
• Cassava Sciences Files 8-K/A Amendment — 8-K/A · Dec 22, 2025 Risk: low
  Cassava Sciences, Inc. filed an 8-K/A on December 22, 2025, to amend a previous filing regarding events that occurred on October 21, 2025. The amendment pertain
• 8-K Filing — 8-K · Dec 18, 2025
• Cassava Sciences Files 8-K on Director Changes — 8-K · Dec 17, 2025 Risk: medium
  On December 12, 2025, Cassava Sciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates th
• Cassava Sciences Files 8-K Report — 8-K · Dec 3, 2025 Risk: medium
  On November 26, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing indicates that the company is providing information under 'Other Events'. Specific
• Cassava Sciences Files 8-K on Operations and Finances — 8-K · Nov 12, 2025 Risk: low
  Cassava Sciences, Inc. filed an 8-K on November 12, 2025, reporting on its results of operations and financial condition, as well as submitting financial statem
• Cassava Sciences Swings to $78.4M Loss Amid R&D Cuts — 10-Q · Nov 12, 2025 Risk: high
  Cassava Sciences Inc. (FLNA) reported a significant net loss of $78.434 million for the nine months ended September 30, 2025, a substantial decline from a net i
• Cassava Sciences Files 8-K Report — 8-K · Oct 24, 2025 Risk: medium
  On October 23, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but the specific details of this event are not pro
• Cassava Sciences Files 8-K: Director Changes & Compensation Updates — 8-K · Oct 22, 2025 Risk: medium
  On October 21, 2025, Cassava Sciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the
• Cassava Sciences Files 8-K with Corporate Updates — 8-K · Sep 8, 2025 Risk: low
  Cassava Sciences, Inc. filed an 8-K on September 8, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
• Cassava Sciences Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  Cassava Sciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition, and including financial statements and e
• Cassava Sciences Swings to $67.6M Loss Amid R&D Cuts — 10-Q · Aug 14, 2025 Risk: high
  Cassava Sciences, Inc. reported a significant net loss of $67.6 million for the six months ended June 30, 2025, a substantial decline from the net income of $31
• Cassava Sciences Files 8-K with Regulatory Updates — 8-K · Aug 4, 2025 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on August 4, 2025, reporting on various events. The filing includes information on Regulation FD disclosures, other events,
• Cassava Sciences Files 8-K: Regulation FD & Exhibits — 8-K · Jun 30, 2025 Risk: low
  On June 30, 2025, Cassava Sciences, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly k
• Cassava Sciences Files 8-K: Director Changes, Shareholder Votes, Financials — 8-K · May 27, 2025 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on May 27, 2025, reporting events as of May 23, 2025. The filing indicates changes related to directors and officers, the su
• Cassava Sciences Files 8-K on Financials — 8-K · May 8, 2025 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as presenting financial statements a
• Cassava Sciences Q1 2025: Assets Surge, Net Loss Widens — 10-Q · May 8, 2025 Risk: high
  Cassava Sciences Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial statements show minimal revenue, with $0.001 milli
• Cassava Sciences: Director Departs, New CMO Elected — 8-K · Apr 21, 2025 Risk: medium
  On April 15, 2025, Cassava Sciences, Inc. filed an 8-K report detailing the departure of Dr. James M. Gill as a director, effective April 15, 2025. The filing a
• Cassava Sciences Files 2025 DEF 14A — DEF 14A · Apr 14, 2025 Risk: medium
  Cassava Sciences Inc. filed a DEF 14A on April 14, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corpo
• Cassava Sciences Files 8-K Report — 8-K · Mar 25, 2025 Risk: low
  On March 25, 2025, Cassava Sciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
• Cassava Sciences Shuffles Top Medical and Scientific Roles — 8-K · Mar 11, 2025 Risk: medium
  On March 6, 2025, Cassava Sciences, Inc. filed an 8-K report detailing the departure of Dr. Feng-Joon (Frank) Chen from his roles as Chief Medical Officer and C
• Cassava Sciences Files 8-K on Financials — 8-K · Mar 3, 2025 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on March 3, 2025, reporting on its results of operations and financial condition, and also including financial statements an
• Cassava Sciences Board Oversees Enterprise Risk Management — 10-K · Mar 3, 2025 Risk: medium
  Cassava Sciences Inc. filed its 2024 10-K on March 3, 2025, detailing its fiscal year ending December 31, 2024. The company's Board of Directors oversees risk m
• Cassava Sciences Files 8-K: Material Agreement & Disclosures — 8-K · Feb 27, 2025 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on February 27, 2025, reporting on a material definitive agreement and Regulation FD disclosure. The filing also includes fi
• Cassava Sciences Files 8-K on Operations and Financials — 8-K · Jan 7, 2025 Risk: medium
  On January 7, 2025, Cassava Sciences, Inc. filed an 8-K report detailing significant events. The filing indicates the company is reporting on its results of ope
• Cassava Sciences Files 8-K — 8-K · Nov 25, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on November 25, 2024, reporting other events and financial statements. The company, previously known as Pain Therapeutics In
• Cassava Sciences Files 8-K on Financials — 8-K · Nov 7, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as submitting financial stateme
• Cassava Sciences Reports $0 Revenue, Increased Expenses — 10-Q · Nov 7, 2024 Risk: high
  Cassava Sciences Inc. filed its 10-Q for the period ending September 30, 2024. The company reported $0 in revenue for the three and nine months ended September
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Cassava Sciences Files 8-K — 8-K · Oct 8, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on October 8, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Cassava Sciences amends 8-K, Officer Changes — 8-K/A · Oct 1, 2024 Risk: medium
  Cassava Sciences, Inc. filed an amendment (8-K/A) on October 1, 2024, to its report originally dated September 6, 2024. This amendment primarily concerns the de
• Cassava Sciences Files 8-K — 8-K · Sep 27, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on September 27, 2024, reporting on events as of September 26, 2024. The filing primarily concerns Regulation FD Disclosure,
• Cassava Sciences Files 8-K for Financials — 8-K · Sep 17, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on September 17, 2024, reporting an event that occurred on September 13, 2024. The filing is primarily for financial stateme
• Cassava Sciences Board Shake-up: New Director Appointed, One Departs — 8-K · Sep 9, 2024 Risk: medium
  Cassava Sciences, Inc. announced on September 6, 2024, a change in its board of directors. Specifically, Dr. James M. Kuo has resigned from his position as a di
• Cassava Sciences Files 8-K/A Amendment — 8-K/A · Aug 9, 2024 Risk: medium
  Cassava Sciences, Inc. filed an 8-K/A amendment on August 9, 2024, related to its results of operations and financial condition as of August 8, 2024. This filin
• Cassava Sciences Files 8-K on Financials and Listing Status — 8-K · Aug 8, 2024 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing also addresses a notice of del
• Cassava Sciences Q2 2024: Cash Up, Equity Down — 10-Q · Aug 8, 2024 Risk: medium
  Cassava Sciences Inc. reported its Q2 2024 results, ending June 30, 2024. The company's financial statements show significant cash and cash equivalents, with $1
• Cassava Sciences Files 8-K — 8-K · Jul 22, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on July 22, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• Cassava Sciences Issues Shares from Warrant Exercise — 8-K · Jul 18, 2024 Risk: low
  On July 18, 2024, Cassava Sciences, Inc. filed an 8-K report detailing the issuance of 1,111,111 shares of common stock upon the exercise of warrants. This resu
• Cassava Sciences Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Jul 17, 2024 Risk: medium
  On July 15, 2024, Cassava Sciences, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new direct
• Cassava Sciences Updates Business Address — 8-K · Jul 1, 2024 Risk: low
  On July 1, 2024, Cassava Sciences, Inc. filed an 8-K report. The filing indicates a change in the company's business address to 6801 N Capital of Texas Highway,
• Cassava Sciences Appoints New CMO, Adds Directors — 8-K · May 22, 2024 Risk: medium
  Cassava Sciences, Inc. announced on May 20, 2024, the appointment of Dr. Sanford D. Greenberg as Chief Medical Officer and the election of Ms. Mary Ann Gray and
• Cassava Sciences Files 8-K on Shareholder Votes and Financials — 8-K · May 13, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on May 13, 2024, reporting on matters submitted to a vote of security holders and financial statements as of May 9, 2024. Th
• Cassava Sciences Files 8-K on Financials — 8-K · May 10, 2024 Risk: low
  On May 10, 2024, Cassava Sciences, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is involved i
• Cassava Sciences Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  CASSAVA SCIENCES INC (FLNA) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Cassava Sciences Inc. reported $0 in revenue for the quarter ended Mar
• Cassava Sciences Appoints New Chief Medical Officer — 8-K · May 8, 2024 Risk: medium
  On May 8, 2024, Cassava Sciences, Inc. filed an 8-K report detailing the appointment of Dr. Eric D. Newman as Chief Medical Officer. Dr. Newman brings extensive
• Cassava Sciences Files 8-K — 8-K · May 1, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on May 1, 2024, to report other events and financial statements. The filing does not contain specific financial figures or d
• Cassava Sciences Files 8-K — 8-K · Apr 15, 2024 Risk: low
  Cassava Sciences, Inc. filed an 8-K on April 15, 2024, reporting other events and financial statements. The company, previously known as Pain Therapeutics Inc.,
• Cassava Sciences Files Definitive Proxy Statement — DEF 14A · Mar 26, 2024 Risk: low
  CASSAVA SCIENCES INC (FLNA) filed a Proxy Statement (DEF 14A) with the SEC on March 26, 2024. Filing type: DEF 14A (Definitive Proxy Statement). Reporting perio
• Cassava Sciences Files 8-K on Financial Condition — 8-K · Feb 28, 2024 Risk: medium
  Cassava Sciences, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing indicates that the company,

Risk Profile

Risk Assessment: Of FLNA's 47 recent filings, 4 were flagged as high-risk, 23 as medium-risk, and 20 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Cassava Sciences INC's most recent 10-Q filing (Nov 12, 2025):

• Revenue: $0
• Net Income: ($78.4M)
• EPS: ($1.62)
• Debt-to-Equity: 0.59
• Cash Position: $106.08M
• Operating Margin: N/A
• Total Assets: $129.73M
• Total Debt: $48.17M

Key Executives

• Dr. James M. Gill
• Dr. Eric J. Schoen
• Dr. Feng-Joon (Frank) Chen
• Dr. Eric P. Smith
• Dr. Michael L. L. Chen
• Dr. Eric D. Newman
• Dr. James M. Johnson
• Dr. James M. Kuo
• Dr. Sanford D. Greenberg
• Ms. Mary Ann Gray
• Mr. David E. R. Scorey

Industry Context

Cassava Sciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of treatments for neurodegenerative diseases. The industry is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory hurdles. Success is heavily dependent on scientific innovation, securing substantial funding, and navigating complex FDA approval processes.

Top Tags

8-k (8) · financials (8) · 8-K (6) · filing (5) · financial-reporting (5) · financial-condition (5) · sec-filing (5) · disclosure (4) · corporate-governance (4) · biotech (4)

Key Numbers

• Commission File Number: 001-41905 — SEC file number for Cassava Sciences, Inc.
• I.R.S. Employer Identification Number: 91-1911336 — EIN for Cassava Sciences, Inc.
• Net Loss: $78.4M — Increased from a $3.255M net income in the prior year period.
• Cash and Cash Equivalents: $106.08M — Decreased from $128.574M at December 31, 2024.
• Accumulated Deficit: $483.5M — Increased from $405.111M at December 31, 2024, reflecting ongoing losses.
• Research and Development Expenses: $22.7M — Decreased significantly from $49.107M in the prior year period.
• Net Cash Used in Operating Activities: $22.5M — Reduced from $55.664M in the prior year period, but still a significant outflow.
• Shares Outstanding: 48,307,896 — As of November 10, 2025, showing minimal change from September 30, 2025.
• Net Loss Per Share (Diluted): $0.22 — For the three months ended September 30, 2025, compared to $0.58 in 2024.
• Common Shares Outstanding: 48,307,896 — as of August 12, 2025
• Net Loss Per Share, Basic: $0.92 — for three months ended June 30, 2025, compared to $0.13 net income per share in 2024
• SEC File Number: 001-41905 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 91-1911336 — Company's tax identification number.
• Total Assets: $120.0M — As of March 31, 2025, showing a significant increase.
• Revenue: $0.001M — For the three months ended March 31, 2025, reflecting minimal sales.

Related Companies

SAVA

Frequently Asked Questions